CVS Health completes $8 billion acquisition of Signify Health; Carl Icahn says Illumina should bring back its former CEO; Public health experts talk about what it means for the COVID-19 pandemic to end.
Five things for pharma marketers to know: Wednesday, March 29, 2023
Evotec extends its partnership with Bristol Myers Squibb; FDA proposes new baby-formula safety measures after a recall last year led to nationwide shortages; Oscar hires former Aetna CEO Mark Bertolini.
Five things for pharma marketers to know: Tuesday, March 28, 2023
Seagen founder Clay Siegall takes the helm of Morphimmune; Gilead and Pionyr Immunotherapeutics “mutually” agree on a rewrite to their 2020 terms; Moderna and Generation Bio announce a $76 million licensing deal.
Five things for pharma marketers to know: Thursday, March 23, 2023
A Food and Drug Administration advisory committee votes against approval of Biogen’s ALS drug; Tanzania announces an outbreak of the Marburg virus; Dewpoint adds Novo Nordisk to its pharma-rich pipeline.
Five things for pharma marketers to know: Wednesday, March 22, 2023
Thermo Fisher Scientific, Celltrion among those competing to acquire Baxter; The Centers for Disease Control and Prevention says a deadly fungus spread at an “alarming rate” during the COVID-19 pandemic; Artificial intelligence develops a treatment for cancer in just 30 days.
Beyond innovation at ViVE 2023: ESG, DEI expected to attract attention
Both environmental, social, and corporate governance as well as diversity, equity, and inclusion have gained traction in the business world over the past few years.
Five things for pharma marketers to know: Tuesday, March 21, 2023
FDA hints it may be open to approving Biogen’s ALS drug tofersen despite failed Phase III study; BioNTech strikes $200 million deal with OncoC4 to develop cancer antibody drug; Karuna Therapeutics’ schizophrenia treatment shows efficacy in reducing psychosis.
Five things for pharma marketers to know: Monday, March 20, 2023
Analysis of genetic samples from China appears to link the COVID-19 pandemic’s origin to raccoon dogs; FDA commissioner Robert Califf calls on private insurers to invest more in clinical drug research; BioXcel files for cancer subsidiary OnkoXcel to go public.